Alzheimer drug trials reveal systemic biotech incentives, regulatory capture, and global care inequities
Original framing: “Predicting biotech clinical trials & a new Alzheimer’s drug controversy” — STAT News
Scientific evidence for the new tau‑targeting antibody remains limited to surrogate biomarkers, with mixed results on clinical endpoints. Prediction markets, while useful for aggregating expectations, cannot substitute for rigorous, transparent data sharing and pre‑registration of trial protocols. Strengthening open science practices would improve reproducibility and public trust.
The Alzheimer’s drug controversy is a symptom of a biotech ecosystem that privileges marketable hype over equitable health outcomes, reinforced by regulatory capture and a neglect of diverse cultural knowledges.
Historical cycles of failed breakthroughs, coupled with the exclusion of indigenous and marginalised voices, reveal a structural bias that perpetuates inequity. By embedding public adaptive trial networks, community advisory panels, tiered pricing, and integrative care pathways, stakeholders can reorient the system toward inclusive, evidence‑based, and culturally resonant solutions. Actors ranging from governments, NGOs, patient coalitions, and traditional healers must collaborate to dismantle the profit‑centric feedback loop and foster a resilient, globally just approach to dementia care.